Using outmoded dosing structures, oncologists may be giving patients unnecessarily high doses of cancer meds, which provides no added benefit to the patient and, in fact, causes unnecessary side effects.…
The European Medicines Agency (EMA) has given the thumbs up to two COVID-19 antibody therapies from Regeneron-Roche and Celltrion Healthcare, paving the way for imminent approval by the European Commission.…
Lecanemab, the antiamyloid antibody being jointly developed by Eisai and Biogen, grabbed the clinical trial world with a fresh look at extension data and news of its inclusion in an…
The European Medicines Agency (EMA) has recommended including transverse myelitis, a rare form of spinal inflammation, to the list of Johnson & Johnson (J&J) COVID-19 vaccine side effects. Source: Drug…
Moderna and the National Institutes of Health (NIH) are in a patent dispute over the company’s messenger RNA (mRNA)-based COVID-19 vaccine developed with the aid of government scientists. Source: Drug…
Inovio has received the FDA go-ahead for a phase 3 trial of INO-4800, a DNA plasmid vaccine against COVID-19. Source: Drug Industry Daily
The biomarker known as circulating tumor DNA (ctDNA) is well-suited to become an early endpoint in oncology, as it has the potential to improve confidence in the efficacy of novel…
AstraZeneca is setting up a new business unit dedicated to overseeing its vaccines and antibody therapies as it looks to rebound from pandemic-era disappointments related to its COVID-19 jab co-developed…
A new national registry, sponsored by the Alzheimer’s Association, will track real-world outcomes data for Alzheimer’s patients receiving FDA-approved treatments for the disease, including the antiamyloid antibody Aduhelm. Source: Drug…
The problems inherent in studying antibiotic-resistant bacteria could be better solved with a widespread automated system that pulls real-world data from electronic health records (EHR). Source: Drug Industry Daily